替诺福韦较恩替卡韦与乙型肝炎病毒相关肝细胞癌患者更好的预后相关
该研究在韩国一家三级中心纳入2008年11月至2018年12月诊断为肝细胞癌的慢性乙型肝炎患者,比较替诺福韦与恩替卡韦对长期预后的影响。中位随访3.0年,替诺福韦组死亡率34.6%,恩替卡韦组41.2%;替诺福韦组总生存更优(校正风险比0.79,P<.001),倾向性评分匹配分析结果一致。
要点
- 替诺福韦组总生存优于恩替卡韦组,校正风险比0.79(P<.001)。
- 肝细胞癌诊断后2年内风险差异更明显(校正风险比0.50,P<.001)。
- 较早肝细胞癌分期患者中替诺福韦的生存优势更显著。
核心结论
- 在乙型肝炎病毒相关肝细胞癌患者中,替诺福韦治疗者预后优于恩替卡韦治疗者,尤其在生存期较长者中更明显。
研究设计与样本
- 研究纳入2008年11月至2018年12月在韩国一家三级中心诊断为肝细胞癌并接受恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者。
- 采用多因素校正Cox分析和倾向性评分匹配分析评估替诺福韦与恩替卡韦对预后的影响,并进行多种预设亚组分析。
主要发现
- 中位随访3.0年,恩替卡韦组(n=3469)死亡率为41.2%,替诺福韦组(n=3056)死亡率为34.6%。
- 替诺福韦组总生存更优(校正风险比0.79,P<.001),倾向性评分匹配分析结果一致。
- 肝细胞癌诊断后2年内总生存风险差异(校正风险比0.50,P<.001)比诊断前2年(校正风险比0.88,P=.005)更明显。
- 在较早肝细胞癌分期患者中,替诺福韦的生存优势更显著。
- 除寿命较短(如肝功能受损)者外,各亚组中替诺福韦均与更好的总生存相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Whether tenofovir or entecavir has different effects on the prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) in secondary and tertiary preventive settings is still a matter of debate. This study aimed to compare the long-term prognosis of HCC between tenofovir and entecavir in patients with chronic hepatitis B. METHODS: Chronic hepatitis B patients diagnosed with HCC between November 2008 and December 2018 and treated with either entecavir or tenofovir at a tertiary center in Korea were included. The effect of tenofovir compared with entecavir on the prognosis of HBV-related HCC was assessed using multivariable-adjusted Cox and propensity score (PS)-matched analyses. Various predefined subgroup analyses were conducted. RESULTS: During a median follow-up period of 3.0 years, the mortality rate for entecavir-treated patients (n = 3469) was 41.2%, while tenofovir-treated patients (n = 3056) had a mortality rate of 34.6%. Overall survival (OS) was better in the tenofovir group (adjusted hazard ratio [aHR], 0.79; P < .001), which were consistently observed in the PS-matched analysis. The magnitude of the risk difference in OS was more prominent 2 years after the diagnosis of HCC (aHR, 0.50; P < .001) than 2 years before (aHR, 0.88; P = .005), and it was more pronounced in patients with earlier HCC stages. In all subgroups, except for those with shorter life expectancy, such as those with compromised liver function, tenofovir was associated with better OS compared with entecavir. CONCLUSIONS: Among patients with HBV-related HCC, those treated with tenofovir had a better prognosis than those treated with entecavir, particularly among those with prolonged survival.
引用
- Chung SW, Um HJ, Choi WM, et al. Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2024. PMID: 39089518. doi:10.1016/j.cgh.2024.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。